Bridge Biotherapeutics (288330), a South Korean biotech company, may be looking to become the country's answer to Strategy (MSTR) or Metaplanet (3350) by adopting a bitcoin treasury strategy.

Seongnam-based Bridge has received a 25 billion won ($183.3 million) backing from crypto investment firm Parataxis, with which it will build a BTC treasury.

Bridge will change its corporate name to Parataxis Korea and continue to trade on the South Korean stock market KOSDAQ, according to an announcement on Friday.

"Inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the U.S. and Metaplanet in Japan, we believe institutional interest in this space is increasing globally," Parataxis partner Andrew Kim said.

More and more companies are copying the playbook of Strategy, which owns more than 2.8% of all the bitcoin that will ever exist. Tokyo-listed hotel operator turned bitcoin investor Metaplanet holds 10,000 BTC ($1.04 billion), making it the largest holding of a public company outside North America.

These firms have witnessed dramatic appreciation in their share price as traders cash in on them as a bitcoin-proxy asset.

Bridge joins fellow healthcare-adjacent companies Semler Scientific (SMLR) and Prenetics Global (PRE) in adopting a bitcoin treasury strategy.

Parataxis is currently preparing to go public in the U.S. via a special purpose acquisition company (SPAC), SilverBox Corp IV (SBXD).

Bridge shares closed over 20.5% higher on Friday at 943 won ($0.69).

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。